Document Detail

Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment.
MedLine Citation:
PMID:  7852533     Owner:  NLM     Status:  MEDLINE    
We studied the effects of GH administration on myocardial structure and function in 20 patients with hypopituitarism (14 males and 6 females; mean +/- SE age, 47.2 +/- 2.6 yr; range, 31-59 yr) developed in adulthood because of pituitary or parapituitary tumors. All patients had GH deficiency (GHD), as assessed by a GH response of less than 4 micrograms/L to a standard insulin tolerance test (0.05 U kg, iv) and the combined pyridostigmine (120 mg, orally, at -60 min) plus GHRH (1 microgram/kg, iv, at 0 min) test. Patients received either placebo (n = 10) or GH substitution therapy (n = 10; 0.05 U/ GH for 1 yr; 0.03 U/ during the first month). M- and B-mode echocardiography and pulsed Doppler examination of transmitral flow were performed before treatment, 6 months and 1 yr after starting GH or placebo administration, and 15 days and 3 months after GH or placebo withdrawal. Twenty healthy subjects, matched for age, sex, body mass index, and physical activity, served as controls. Left ventricular dimensions, mass, and systolic function were normal in patients with adult-onset GHD; however, diastolic function, specifically E wave deceleration time, was altered. GH administration markedly increased left ventricular performance and reversed diastolic abnormalities at 6 and even more so at 12 months. On the other hand, a clear increase in left ventricular mass was seen after 12, but not after 6, months of GH administration (P < 0.01 vs. pretreatment values). In addition, although all changes induced by GH treatment disappeared within 3 months after GH withdrawal, at that time the increase in left ventricular mass was still detectable (P < 0.05 vs. pretreatment values). These data indicate that augmented left ventricular contractility is not strictly related to cardiac muscle growth, supporting the hypothesis that GH treatment increases the inotropic activity of myocardial fibers. In conclusion, GH treatment enhances cardiac function, increases cardiac mass, and reverses diastolic abnormalities in adults with hypopituitarism and GHD. However, long term studies are required to demonstrate that GH replacement therapy reduces cardiac death rate in these patients.
R Valcavi; O Gaddi; M Zini; M Iavicoli; U Mellino; I Portioli
Related Documents :
10430973 - Echocardiographic evaluation in patients with autosomal dominant polycystic kidney dise...
17131073 - Increased prevalence of concentric left ventricular hypertrophy in african-americans: w...
7674423 - Effects of corticosteroid inhalation therapy on lung ventilation and alveolar permeabil...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  80     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  1995 Feb 
Date Detail:
Created Date:  1995-03-10     Completed Date:  1995-03-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  659-66     Citation Subset:  AIM; IM    
2a Divisione di Medicina Interna, Arcispedale S. Maria Nuova, Reggio Emilia, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure
Body Mass Index
Body Surface Area
Growth Hormone / adverse effects,  therapeutic use*
Heart / physiopathology*
Heart Rate
Hypopituitarism / drug therapy,  physiopathology*,  ultrasonography*
Insulin-Like Growth Factor I / analysis
Middle Aged
Time Factors
Reg. No./Substance:
67763-96-6/Insulin-Like Growth Factor I; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weigh...
Next Document:  Pharmacokinetics of recombinant human luteinizing hormone after intravenous, intramuscular, and subc...